Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AXS-14 esreboxetine for managing fibromyalgia in a Phase 3, double-blind, placebo-controlled, randomized withdrawal study. The study aims to assess the efficacy and safety of AXS-14 for people diagnosed with fibromyalgia based on the 2016 ACR diagnostic criteria. The trial includes a multi-center design with two main periods. First, participants receive open-label AXS-14 tablets once daily for up to 12 weeks. Those who respond to treatment are then randomized to either continue AXS-14 or switch to placebo for an additional 12 weeks or until loss of therapeutic response occurs. Participants will be involved for up to 24 weeks in total. During this time, they will take study tablets daily and undergo assessments to monitor their response and safety. The primary outcome measured is the time from randomization to loss of therapeutic response over 12 weeks. Safety and efficacy are closely monitored throughout the study.
Actively Recruiting
Researchers are evaluating a simplified, low-barrier hepatitis C virus HCV treatment program designed for adults with active HCV who are incarcerated and awaiting trial at the Rhode Island Department of Corrections. This study aims to determine whether this approach is feasible, acceptable, and effective in a jail setting, especially for people who inject drugs. It is a pilot study assessing if the treatment can be completed and if participants are cured of HCV using this method, potentially informing future expansion of HCV treatment in correctional facilities. Participants will receive a 12-week course of the medication sofosbuvirvelpatasvir Epclusa without the need for lab monitoring during treatment. If released before completing treatment, participants will take remaining doses with them and receive support from Community Health Workers CHWs. These CHWs will assist with medication adherence, community re-entry, and coordination of follow-up lab work. The study includes one experimental arm where all participants receive the full treatment and CHW support. During the study, participants will be tracked for cure rates of HCV between 12 and 24 weeks after treatment completion. Researchers will also assess how easy the program is to deliver, how well participants follow the treatment plan, and how acceptable the program is to both participants and staff. Additional data collected includes participant demographics, adherence to medication inside and outside jail, program costs, and qualitative feedback from participants and staff. The study will help determine if this treatment model can be maintained and scaled in other jail settings.
Actively Recruiting
This research aims to compare two extended-release buprenorphine medications, Sublocade and Brixadi, for people with opioid use disorder OUD who are leaving prison and reentering the community. The study is a pilot hybrid trial evaluating both how well these treatments work and how feasible and acceptable they are in a correctional setting. It also explores whether allowing participants to choose their medication affects how long they stay in treatment. Participants will receive monthly injections of either Sublocade or Brixadi before and after their release from prison. Some participants will choose which medication they prefer, while others will be randomly assigned to one of the two treatments. The study includes ongoing monthly treatment with flexibility for dosing based on clinical decisions. Participants can switch treatments or stop at any time. During the study, participants will complete surveys and clinical assessments about their treatment experience and satisfaction. Researchers will monitor treatment retention, opioid use through self-report and urine tests, cravings, adverse events, emergency visits, and hospitalizations for six months after release. The study will use these measures to compare the two medications and assess implementation outcomes such as acceptability and feasibility.